 Alpine Immune Sciences Inc NASDAQ: ALPN has entered into a clinical trial collaboration and supply agreement with Merck Co Inc NYSE: MRK. This collaboration will evaluate the safety and efficacy of Alpines ALPN-202 in combination with Mercks Keytruda pembrolizumab in patients with advanced malignancies. 